Tufts Center for the Study of Drug Development, PRTM, and Management Roundtable
64 articles about Tufts Center for the Study of Drug Development, PRTM, and Management Roundtable
-
Streamlined Development Process For Certain New Drug Applications Is Not Facilitating Shorter Approval Times, According To Tufts Center for the Study of Drug Development
1/11/2017
-
New Approaches To Patient Recruitment And Retention Anticipate Structural Change In The Clinical Research Enterprise, Tufts Center for the Study of Drug Development Reports
1/26/2016
-
Personalized Medicine Is Gaining Traction, But Faces Multiple Challenges, Tufts Center for the Study of Drug Development Study Concludes
5/15/2015
-
Biotech Products In Big Pharma Clinical Pipelines Have Grown Dramatically According To The Tufts Center for the Study of Drug Development
11/14/2013
-
Biotech Products Dominate Clinical Trial Pipelines And Sales Of Big Pharma, According To The Tufts Center for the Study of Drug Development
11/14/2013
-
Drug Industry Leaders See Collaboration as Key to Greater Productivity, According to Tufts Center for the Study of Drug Development
8/13/2013
-
Aptiv Solutions Release: Tufts Center for the Study of Drug Development Study Finds Adoption of Adaptive Clinical Trial Designs Is Increasing
5/23/2013
-
Investigative Site Landscape Remains Highly Fragmented as the Number of Active Investigators Worldwide Reaches an All-Time High, According to the Tufts Center for the Study of Drug Development
3/12/2013
-
Companion Diagnostics, Key to Development of Personalized Medicines, Face Hurdles, According to Tufts Center for the Study of Drug Development
1/24/2013
-
New Research From Tufts Center for the Study of Drug Development Characterizes Effectiveness and Variability of Patient Recruitment and Retention Practices
1/15/2013
-
Extraneous Data Collected in Clinical Trials Cost Drug Developers $4 Billion to $6 Billion Annually, According to Tufts Center for the Study of Drug Development
11/6/2012
-
Contract Support and Technical Service Providers Expected to Play a Growing Role in Drug Development, According to Tufts Center for the Study of Drug Development
10/17/2012
-
U.S. Patients Get More Cancer Drugs Access, But Pay for Privilege, Tufts Center for the Study of Drug Development Study
7/11/2012
-
U.S. Cancer Patients Get Faster Access to More Oncology Drugs Than European Patients, According to Tufts Center for the Study of Drug Development
7/10/2012
-
Clinical Trials Can Waste How Much Money? Tufts Center for the Study of Drug Development Study
7/10/2012
-
Drug Sponsors' Regulatory Experience Was Mixed During PDUFA IV, According to Tufts Center for the Study of Drug Development
5/9/2012
-
Drug Companies are Looking to Shorten Time to Early Clinical Development, According to Tufts Center for the Study of Drug Development
4/26/2012
-
Drugs to Treat CNS Diseases Take 35% Longer to Develop Than Other Drugs, According to Tufts Center for the Study of Drug Development
3/7/2012
-
Drug Company Executives are Expanding Their Use of Strategic Partnerships, According to Tufts Center for the Study of Drug Development
1/26/2012
-
Tufts Center for the Study of Drug Development Establishes Workload and Utilization Benchmarks for Global Clinical Research Associates
1/17/2012